Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
IHL-42X is the Company’s proprietary fixed dose combination drug for treatment of obstructive sleep apnea.
- IHL-42X is the Company’s proprietary fixed dose combination drug for treatment of obstructive sleep apnea.
- Furthermore, 25% of patients experienced a reduction in AHI of greater than 80%, representing a sub clinical AHI score for some trial participants.
- Dr Mark Bleackley, Incannex Chief Scientific Officer said, “Patient dosing in the RePOSA study represents a critical step forward in the development of IHL-42X for treatment of obstructive sleep apnea.
- Phase 2 of the RePOSA study will be conducted at 25 sites in the United States.